N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

RAT-HEMATO : Return to Work After Malignant Hemopathy

Sponsor: University Hospital, Angers • ClinicalTrials.gov ID: NCT06262789

Registry updated: 2026-09-04
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.

Interventions

  • "Return-to-work after cancer" consultation (Other)
    The "return-to-work after cancer" consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation.

Eligibility criteria

Inclusion Criteria : * Patient with hematological malignancy controlled after treatment * Induction/consolidation chemotherapy completed (excluding maintenance therapy) * Patient aged 18 to 55 * Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy * Patient who has not yet returned to work since diagnosis of hematological malignancy * Signed informed consent form Exclusion Criteria: * Patient choosing not to return to work * Patient not affiliated to a social security system * Patient with legal guardian or legal trustee * Patient not understanding French * Patient with severe cognitive impairment at diagnosis, incompatible with the study

Conditions

Leukemia Lymphoma Multiple Myeloma

Locations

  • Angers University hospital — Angers, France
  • Brest University Hospital, Morvan Site — Brest, France
  • Caen University hospital — Caen, France
  • Service Hématologie, Cholet Hospital — Cholet, France
  • Le Havre Hospital Group — Montivilliers, France
  • Pays de Morlaix Hospital — Morlaix, France
  • Rennes University Hospital, Pontchaillou site — Rennes, France
  • Centre Henri Becquerel — Rouen, France
  • Rouen University Hospital — Rouen, France
  • Tours University Hospital, Bretonneau Site — Tours, France
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record